Search Results

Deals

GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines

GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.

July 3, 2024

·

2 min read

·

Tristan Manalac

Press Releases

CureVac to Present at the 12th International mRNA Health Conference

November 5, 2024

·

6 min read

Business

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2024 and provided a business update.

May 23, 2024

·

12 min read

Press Releases

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 28, 2024

·

5 min read

Press Releases

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

November 13, 2024

·

20 min read

Business

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac N.V. today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.

April 24, 2024

·

7 min read

Business

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

CureVac N.V. today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK.

May 28, 2024

·

6 min read

Press Releases

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

November 5, 2024

·

6 min read

Business

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

April 16, 2024

·

8 min read

Business

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update.

April 24, 2024

·

21 min read